Alvotech Gets A Fresh Date For Adalimumab In US
Expects FDA Reinspection Ahead Of 24 February 2024 Goal Date For Humira Biosimilar
Alvotech has revealed a US FDA goal date of 24 February 2024 for its refiled AVT02 proposed high-concentration interchangeable adalimumab biosimilar rival to Humira, as the firm provided further details of the resubmission – including an expected facility reinspection.
